[Re-allign (randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran ftexilate in patients after heart valve replacement)]

Internist (Berl). 2014 Sep;55(9):1108-9, 1111. doi: 10.1007/s00108-014-3559-x.
[Article in German]
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Aged
  • Antithrombins / administration & dosage
  • Antithrombins / adverse effects
  • Antithrombins / pharmacokinetics
  • Benzimidazoles / administration & dosage
  • Benzimidazoles / adverse effects*
  • Benzimidazoles / pharmacokinetics*
  • Dabigatran
  • Female
  • Heart Valve Prosthesis Implantation / adverse effects*
  • Humans
  • Male
  • Metabolic Clearance Rate
  • Middle Aged
  • Thrombosis / etiology
  • Thrombosis / metabolism*
  • Thrombosis / prevention & control*
  • Tissue Distribution
  • Treatment Outcome
  • Young Adult
  • beta-Alanine / administration & dosage
  • beta-Alanine / adverse effects
  • beta-Alanine / analogs & derivatives*
  • beta-Alanine / pharmacokinetics

Substances

  • Antithrombins
  • Benzimidazoles
  • beta-Alanine
  • Dabigatran